Antiviral activity of coxsackievirus B3 3C protease inhibitor in experimental murine myocarditis

33Citations
Citations of this article
24Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background. We investigated the efficacy of a 3C protease inhibitor (3CPI) in a murine coxsackievirus B3 (CVB3) myocarditis model. CVB3 is a primary cause of viral myocarditis. The CVB3 genome encodes a single polyprotein that undergoes a series of proteolytic events to produce several viral proteins. Most of this proteolysis is catalyzed by the 3C protease (3CP). Methods and Results. By way of a micro-osmotic pump, each mouse received 50 mM 3CPI in 100 μL of 100% dimethyl sulfoxide (DMSO) during a 72-hour period. On the day of pump implantation, mice (n = 40) were infected intraperitoneally with 10 6 plaque-forming units of CVB3. For the infected controls (n = 50), the pump was filled with 100% DMSO without 3CPI. The 3-week survival rate of 3CPI-treated mice was significantly higher than that of controls (90% vs 22%; P

Cite

CITATION STYLE

APA

Yun, S. H., Lee, W. G., Kim, Y. C., Ju, E. S., Lim, B. K., Choi, J. O., … Jeon, E. S. (2012). Antiviral activity of coxsackievirus B3 3C protease inhibitor in experimental murine myocarditis. Journal of Infectious Diseases, 205(3), 491–497. https://doi.org/10.1093/infdis/jir745

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free